PT3484467T - Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase - Google Patents

Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase

Info

Publication number
PT3484467T
PT3484467T PT167666221T PT16766622T PT3484467T PT 3484467 T PT3484467 T PT 3484467T PT 167666221 T PT167666221 T PT 167666221T PT 16766622 T PT16766622 T PT 16766622T PT 3484467 T PT3484467 T PT 3484467T
Authority
PT
Portugal
Prior art keywords
pure
combination
receptor antagonists
acetylcholinesterase inhibitors
acetylcholinesterase
Prior art date
Application number
PT167666221T
Other languages
English (en)
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of PT3484467T publication Critical patent/PT3484467T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT167666221T 2016-05-18 2016-08-03 Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase PT3484467T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201641017205 2016-05-18

Publications (1)

Publication Number Publication Date
PT3484467T true PT3484467T (pt) 2020-06-16

Family

ID=56940098

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167666221T PT3484467T (pt) 2016-05-18 2016-08-03 Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase

Country Status (28)

Country Link
US (1) US11458135B2 (pt)
EP (1) EP3484467B1 (pt)
JP (1) JP6606299B2 (pt)
KR (1) KR102015484B1 (pt)
CN (2) CN114642667A (pt)
AU (1) AU2016407427B2 (pt)
BR (1) BR112018073419A2 (pt)
CA (1) CA3023819C (pt)
CY (1) CY1123013T1 (pt)
DK (1) DK3484467T3 (pt)
EA (1) EA036347B1 (pt)
ES (1) ES2796181T3 (pt)
HR (1) HRP20200872T1 (pt)
HU (1) HUE050819T2 (pt)
IL (1) IL262921B (pt)
LT (1) LT3484467T (pt)
MA (1) MA45639B1 (pt)
MD (1) MD3484467T2 (pt)
ME (1) ME03731B (pt)
MX (1) MX2018014185A (pt)
NZ (1) NZ748280A (pt)
PL (1) PL3484467T3 (pt)
PT (1) PT3484467T (pt)
RS (1) RS60422B1 (pt)
SG (1) SG11201809856SA (pt)
SI (1) SI3484467T1 (pt)
WO (1) WO2017199071A1 (pt)
ZA (1) ZA201807468B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111084776A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
AU2020398082A1 (en) * 2019-12-02 2022-06-16 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
KR20220110518A (ko) 2019-12-02 2022-08-08 수벤 라이프 사이언시스 리미티드 치매 환자의 행동 및 심리적 증상 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509982C (en) * 2002-11-28 2011-11-08 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CA2658959A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
IN2013CH05537A (pt) * 2013-12-02 2015-06-12 Suven Life Sciences Ltd

Also Published As

Publication number Publication date
JP2019516699A (ja) 2019-06-20
ME03731B (me) 2021-01-20
JP6606299B2 (ja) 2019-11-13
IL262921A (en) 2018-12-31
US20190125743A1 (en) 2019-05-02
BR112018073419A2 (pt) 2019-03-19
DK3484467T3 (da) 2020-06-08
HUE050819T2 (hu) 2021-01-28
AU2016407427A1 (en) 2018-11-22
NZ748280A (en) 2020-07-31
CN114642667A (zh) 2022-06-21
CA3023819C (en) 2019-10-22
SG11201809856SA (en) 2018-12-28
PL3484467T3 (pl) 2020-08-24
ZA201807468B (en) 2020-02-26
MX2018014185A (es) 2019-02-25
CN109069468A (zh) 2018-12-21
EA201892529A1 (ru) 2019-03-29
WO2017199071A1 (en) 2017-11-23
EA036347B1 (ru) 2020-10-29
LT3484467T (lt) 2020-07-10
MA45639B1 (fr) 2020-06-30
KR102015484B1 (ko) 2019-08-28
EP3484467A1 (en) 2019-05-22
SI3484467T1 (sl) 2020-10-30
RS60422B1 (sr) 2020-07-31
CA3023819A1 (en) 2017-11-23
CY1123013T1 (el) 2021-10-29
MD3484467T2 (ro) 2020-06-30
ES2796181T3 (es) 2020-11-26
US11458135B2 (en) 2022-10-04
EP3484467B1 (en) 2020-04-29
HRP20200872T1 (hr) 2020-11-27
AU2016407427B2 (en) 2019-11-21
KR20190002700A (ko) 2019-01-08
IL262921B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
SI3125893T1 (sl) Devterirani heterociklični zliti gama-karbolini kot antagonisti receptorjev 5-HT2A
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
IL284005A (en) Glucocorticoid receptor inhibitors
IL262921B (en) Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors
IL251725A0 (en) Dopamine d3 receptor antagonist compounds
HK1258023A1 (zh) 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合
HK1258022A1 (zh) 純5-ht6受體拮抗劑、乙醯膽鹼酯酶抑制劑和nmda受體拮抗劑的三重組合
HK1250163A1 (zh) 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法
IL264406B (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
ZA202000758B (en) Fluoropiperidine compounds as pure 5-ht6 receptor antagonists